Skip to main content

Amneal Pharmaceuticals, Inc. (AMRX)

NYSE: AMRX · IEX Real-Time Price · USD
4.25 -0.37 (-8.01%)
Nov 26, 2021 1:00 PM EST - Market closed
Market Cap634.83M
Revenue (ttm)2.07B
Net Income (ttm)13.96M
Shares Out149.37M
EPS (ttm)0.09
PE Ratio46.20
Forward PE6.30
Dividendn/a
Ex-Dividend Daten/a
Volume960,796
Open4.81
Previous Close4.62
Day's Range4.23 - 4.48
52-Week Range3.90 - 7.45
Beta1.25
AnalystsHold
Price Target7.17 (+68.7%)
Earnings DateNov 5, 2021

About AMRX

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates in three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the d...

IndustryPharmaceuticals
Founded2002
Employees6,000
Stock ExchangeNYSE
Ticker SymbolAMRX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for AMRX stock is "Hold." The 12-month stock price forecast is 7.17, which is an increase of 68.71% from the latest price.

Price Target
$7.17
(68.71% upside)
Analyst Consensus: Hold

News

Amneal Receives Approval for Difluprednate Ophthalmic Emulsion

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U...

1 week ago - Business Wire

Amneal to Virtually Participate at Upcoming Investor Conferences

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that its investor relations or management team will virtually attend the following investor ...

2 weeks ago - Business Wire

Amneal Posts Mixed Bag Q3 Earnings; Acquires Puniska To Bolster Injectable Business

Amneal Pharmaceuticals Inc (NYSE: AMRX) reports Q3 revenue of $529 million, a marginal increase of 2% Y/Y, missing the consensus of $545.06 million. The increase was driven by Generic product launches a...

3 weeks ago - Benzinga

Amneal Pharmaceuticals (AMRX) Tops Q3 Earnings Estimates

Amneal (AMRX) delivered earnings and revenue surprises of 5.00% and -3.27%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

3 weeks ago - Zacks Investment Research

Amneal Reports Third Quarter 2021 Financial Results

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) announced its results today for the third quarter ended September 30, 2021. “Our solid third qua...

3 weeks ago - Business Wire

Amneal Releases Inaugural Corporate Responsibility Report Highlighting Our Impact as a Socially Responsible Company

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced the release of its inaugural Corporate Responsibility Report with primarily 2020...

3 weeks ago - Business Wire

Amneal Pharmaceuticals (AMRX) to Report Q3 Results: Wall Street Expects Earnings Growth

Amneal (AMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 weeks ago - Zacks Investment Research

Amneal Launches Generic Dexamethasone Following ANDA Approval by FDA

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that it is launching dexamethasone, 4mg and 6 mg, following Abbreviated New Drug...

1 month ago - Business Wire

Why the Earnings Surprise Streak Could Continue for Amneal (AMRX)

Amneal (AMRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

1 month ago - Zacks Investment Research

Amneal to Report Third Quarter 2021 Results on November 3, 2021

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its third quarter 2021 financial results on Wednesday, November 3, 2021, prior...

1 month ago - Business Wire

Amneal to Virtually Participate at Morgan Stanley 19th Annual Global Healthcare Conference

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that members of management will participate at the Morgan Stanley Global Healthcare Conferen...

2 months ago - Business Wire

Amneal (AMRX) Parkinson's Candidate Successful in Pivotal Study

Amneal's (AMRX) IPX-203 increases "Good On" time by 1.55 hours per dose versus immediate-release CD/LD in patients with Parkinson's disease.

3 months ago - Zacks Investment Research

Amneal's Parkinson's Candidate Shows Efficacy In Pivotal Trial

Amneal Pharmaceuticals Inc (NYSE: AMRX) announced topline data from the Phase 3 RISE-PD trial evaluating IPX-203 in patients with Parkinson's disease who have motor fluctuations.  Amneal plans to submit...

3 months ago - Benzinga

Amneal Announces Positive Topline Results from Pivotal Phase 3 RISE-PD Clinical Trial of IPX-203 in Patients with Par...

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced positive topline results from the pivotal Phase 3 RISE-PD clinical trial that evaluated the novel formulatio...

3 months ago - Business Wire

Amneal Announces Virtual Event to Discuss Initial Data from Pivotal Phase 3 Study of IPX-203 in Patients with Parkins...

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that it will host a virtual event for the investment community on Wednesday, August 25, 2021 at 4:30 p.m. ET...

3 months ago - Business Wire

Amneal Pharmaceuticals (AMRX) Q2 Earnings and Revenues Top Estimates

Amneal (AMRX) delivered earnings and revenue surprises of 38.89% and 1.86%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Amneal Q2 Earnings Tops Estimates; Backs FY21 Guidance

Amneal Pharmaceuticals Inc (NYSE: AMRX) reports Q2 revenue of $535 million, an increase of 15% Y/Y, beating the consensus of $523.25 million. Sales growth was driven by Generic product launches, special...

3 months ago - Benzinga

Amneal Pharmaceuticals: Q2 Earnings Insights

Shares of Amneal Pharmaceuticals (NYSE:AMRX) moved higher by 0.6% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share increased 92.31% year over year to $0....

3 months ago - Benzinga

Amneal Reports Second Quarter 2021 Financial Results

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE:AMRX) (the “Company”) announced its results today for the second quarter ended June 30, 2021. “Our strong second quarter results re...

3 months ago - Business Wire

Amneal Pharmaceuticals (AMRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Amneal (AMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

Amneal Receives Approval for Generic TobraDex®

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U...

4 months ago - Business Wire

Amneal to Report Second Quarter 2021 Results on August 9, 2021

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its second quarter 2021 financial results on Monday, August 9, 2021, prior to ...

4 months ago - Business Wire

10 Stocks Under $10 to Buy In July for the Rest of the Year

10 Stocks to watch now trading under $10 with significant upside potential The post 10 Stocks Under $10 to Buy In July for the Rest of the Year appeared first on InvestorPlace. More From InvestorPlace S...

4 months ago - InvestorPlace

AMRX vs. ZTS: Which Stock Should Value Investors Buy Now?

AMRX vs. ZTS: Which Stock Is the Better Value Option?

Other symbols:ZTS
4 months ago - Zacks Investment Research

Amneal's Avastin-Referred Biosimilar Under FDA Review For Colorectal Cancer

The FDA has accepted for review Amneal Pharmaceuticals Inc's (NYSE: AMRX) marketing application seeking approval for Bevacizumab, under Section 351(k) pathway of the Public Health Service Act. The cover...

5 months ago - Benzinga